If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Directorate Change

23 Jul 2015 13:35

RNS Number : 9253T
Imperial Innovations Group plc
23 July 2015
 



23 July 2015

 

Imperial Innovations Group plc

 

Directorate Change

 

Imperial Innovations Group plc (AIM: IVO, 'the Group', 'Innovations') announces that its non-executive director Mark Rowan will resign from the Board on 31 July 2015.

 

Mark was appointed to the Board in April 2006, having been a director of the Group's subsidiary Imperial Innovations Ltd since January 2005. He joined Innovations after a career working at J.P. Morgan and American International Group and has also provided advice on strategic and structural issues to a broad spectrum of companies, including early-stage technology investments.

 

Mark served as the Chairman of the Group's Audit and Risk Committee since the Group's IPO in 2006. He also served on the Remuneration Committee and Nomination Committee.

 

Linda Wilding takes over as chair of the Audit and Risk Committee on 1 August 2015.

 

Martin Knight, Chairman of Imperial Innovations, said:

 

"On behalf of the Board I would like to thank Mark for more than ten years of service to the Group, during which time we have benefited from his extensive experience, wise counsel and financial expertise.

 

"He has played an important role in Innovations' evolution, from its IPO in 2006, to its current position as one of the UK's leading technology commercialisation companies.

 

"His legacy includes our sound financial controls and funding strategy, recent highlights of which include the execution of last year's £150m placing and obtaining £80m in loan facilities from the European Investment Bank (EIB).

 

"Mark has made a significant contribution to the success of the Group and we would all like to thank him for his service and offer him our best wishes for the future."

 

For further information contact:

 

Imperial Innovations Group plc

020 3053 8834

Martin Knight, Chairman

Jon Davies, Director of Communications

 

Instinctif Partners

020 7457 2020

Adrian Duffield/Melanie Toyne-Sewell

 

J.P. Morgan Cazenove (Nominated Adviser)

020 7742 4000

Michael Wentworth-Stanley/Alec Pratt

 

Cenkos Securities

020 7397 8900

Christopher Golden

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUCWMUPAGPW
Date   Source Headline
28th Jul 20157:01 amRNS£1 million seed investment in Inflowmatix
27th Jul 20157:00 amRNS£3.0 million investment in Concirrus
23rd Jul 20151:35 pmRNSDirectorate Change
14th Jul 20157:00 amRNSFurther £50m loan facility from EIB
2nd Jul 20157:00 amRNS£4.0m funding round in Impression Technologies
1st Jul 20157:00 amRNSFirst subject enrolled in Veryan Medical's study
30th Jun 20157:00 amRNSLeads £3 million investment in Abingdon Health
8th Jun 20151:18 pmRNSDirectorate Change
3rd Jun 20157:00 amRNSInnovations leads £6m funding round in Auspherix
29th May 20157:00 amRNSAppointment of Executive Chairman at Kesios
27th May 20154:05 pmRNSHolding(s) in Company
26th May 20157:01 amRNSDivests its shares of Epigeum
19th May 20157:00 amRNS£25m Series C funding round in PsiOxus
14th May 20157:00 amRNSTopiVert starts Phase I Clinical Trial
30th Apr 20153:48 pmRNSDirector's share purchase
27th Apr 20157:00 amRNSAutifony Therapeutics recruits first trial patient
15th Apr 20157:00 amRNSInnovations leads £5.9m funding round in Yoyo
27th Mar 20157:00 amRNSHalf Yearly Report
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
18th Mar 20157:00 amRNSCell Medica granted Orphan Drug designation
13th Mar 201510:07 amRNSEdison publishes research on Imperial Innovations
27th Feb 201511:48 amRNSNotice of Results
19th Feb 20157:00 amRNSCell Medica to commence cell therapy manufacture
14th Jan 201512:13 pmRNS£18 million Series B funding round in Veryan
18th Dec 20147:00 amRNSImperial named UK's top research university
16th Dec 201411:39 amRNSResult of AGM
9th Dec 20142:55 pmRNSGrant of options under SAYE Scheme
26th Nov 20143:41 pmRNSGrant of share options
25th Nov 201410:45 amRNSReplacement Director's share purchase
25th Nov 20147:00 amRNS£50 million Series B funding round in Cell Medica
24th Nov 20144:20 pmRNSDirector's share sale
12th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
24th Oct 20147:00 amRNSDirectorate Changes
15th Oct 20147:00 amRNSFinal Results
8th Oct 20147:00 amRNSInnovations invests £1.85m in Kesios Therapeutics
5th Sep 20141:55 pmRNSNotice of Results
13th Aug 201412:43 pmRNSDirector's share sale
15th Jul 20142:08 pmRNSDirectorate Change
7th Jul 20147:14 amRNSPortfolio company Abzena announces offer price
4th Jul 20143:36 pmRNSHolding(s) in Company
23rd Jun 20143:15 pmRNSResults of Placing
23rd Jun 20147:00 amRNSPlacing to raise £150 million
19th Jun 201412:45 pmRNSResult of General Meeting
16th Jun 20147:09 amRNSPortfolio company announces intention to float
12th Jun 20147:00 amRNSImperial Innovations invests £1.5m in Cortexica
10th Jun 20147:00 amRNS£3 million funding round for Featurespace
4th Jun 20147:00 amRNSAutifony receives funding for Phase II trial
2nd Jun 20147:00 amRNSAppointment of non-executive directors
2nd Jun 20147:00 amRNSProposed Placing to raise up to £150 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.